Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

54.05 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

January 08, 2024

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

December 04, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

February 28, 2024

Via Benzinga

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

February 22, 2024

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

December 08, 2023

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

November 07, 2023

Via Benzinga

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

December 02, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today ↗

November 30, 2023

Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542...

Via Benzinga

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

November 29, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Announces Proposed Public Offering

November 29, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 28, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst ↗

November 27, 2023

Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20...

Via Benzinga

Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 27, 2023

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.

Via Benzinga

The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring ↗

November 27, 2023

The company's epilepsy drug also showed promise as a depression treatment.

Via Investor's Business Daily

What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today? ↗

November 27, 2023

Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of...

Via Benzinga

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Near the Top of Equities by Percentage Gain on 11/27

November 27, 2023

Via Investor Brand Network

Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday ↗

November 27, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company...

Via Benzinga

Topics Stocks

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

November 27, 2023

Conference call today at 8:30 am ET

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗

November 10, 2023

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)

Via Benzinga

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

November 09, 2023

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 08, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

November 01, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Earnings Scheduled For November 8, 2023 ↗

November 08, 2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

Via Benzinga

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

October 09, 2023

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.